Natco Pharma shares tank 19%, near 52-week low on weak Q3 results

Quick Summary:

It has corrected 41 per cent from its 52-week high level of Rs 1,685.35 touched on September 12, 2024.

Earnings before interest, tax, depreciation and amortisation (Ebitda) margin decreased to 33.0 per cent in Q3FY25 from 38.3 per cent in Q3FY24 and 60.5 per cent in Q2FY25.

Consolidated profit after tax (PAT) declined 37.8 per cent year-on-year (YoY), at Rs 132.40 crore.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Category: BusinessFinance

Markets: IndiaBrazilCanada

Topics: Natco pharma share Finished dosage formulations Natco pharma Natco pharma share price Natco pharma results API Markets Q3 Agrochemicals FDF Pharmaceuticals Natco pharma news Why natco pharma is falling Active Pharmaceutical Ingredient Natco share price Natco Pharma share Export formulation business

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2025-02-13 @ 10:34:41 (12 hours ago)

News Timezone: GMT +5:00

News Source URL: business-standard.com

Language: English

Article Length: 551 words

Reading Time: 4 minutes read

Sentences: 30 lines

Sentence Length: 19 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Business Standard

News ID: 26111924

View Article Analysis

About Business Standard

Main Topics: BusinessFinance

Official Website: business-standard.com

Update Frequency: 272 posts per day

Year Established: 1975

Headquarters: India

News Last Updated: 3 hours ago

Coverage Areas: India

Ownership: Independent Company

Publication Timezone: GMT +5:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #49

Publisher Details

Frequently Asked Questions